Last $6.90 USD
Change Today 0.00 / 0.00%
Volume 30.8K
MEIP On Other Exchanges
As of 5:20 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

mei pharma inc (MEIP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/28/14 - $13.98
52 Week Low
06/25/14 - $5.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEI PHARMA INC (MEIP)

Related News

No related news articles were found.

mei pharma inc (MEIP) Related Businessweek News

No Related Businessweek News Found

mei pharma inc (MEIP) Details

MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also includes ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

mei pharma inc (MEIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $675.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $343.8K
Chief Medical Officer
Total Annual Compensation: $241.2K
Compensation as of Fiscal Year 2013.

mei pharma inc (MEIP) Key Developments

MEI Pharma, Inc. Announces Cash Flow Results for the Fourth Quarter and Earnings Results for the Fiscal Year Ended June 30, 2014

MEI Pharma, Inc. announced cash flow results for the fourth quarter and earnings results for the fiscal year ended June 30, 2014. For the year, the company’s loss from operations was $27,228,000 against $11,222,000 a year ago. Net loss was $27,148,000 or $1.35 per basic and diluted share against $11,186,000 or $1.10 per basic and diluted share a year ago. Net cash used in operations was $19.5 million compared to $10.0 million for 2013. For the quarter ended June 30, 2014, net cash used in operations was $5.9 million.

MEI Pharma, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 08:30 AM

MEI Pharma, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 08:30 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Daniel P. Gold, Chief Executive Officer, President and Director.

MEI Pharma, Inc. Completes Enrollment in Randomized Phase II Clinical Trial of Pracinostat in Combination with Azacitidine

MEI Pharma, Inc. announced that it has completed enrollment in a randomized Phase II clinical trial of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). The multi-center, placebo-controlled, double-blind study enrolled a total of 108 patients with a one-to-one randomization. The company plans to unblind the study approximately six months after the last patient was enrolled and report topline data in first quarter of 2015. The randomized Phase II study is designed to evaluate the safety and efficacy of Pracinostat compared to placebo when combined with azacitidine, a drug approved by the U.S. Food and Drug Administration for the treatment of MDS. The primary endpoint of the study is rate of complete remission (CR). Secondary endpoints include overall response rate, hematologic improvement, duration of response, progression-free survival, rate of leukemic transformation, and overall survival and safety. Results from an earlier pilot study of Pracinostat in combination with azacitidine in patients with intermediate-2 or high-risk MDS presented at the American Society of Hematology Annual Meeting in December 2012 reported an overall response rate of 89% (eight out of nine), including seven patients who achieved either a CR or a complete remission with incomplete blood count recovery (CRi). Combined with the results from an additional patient treated at the University of Wisconsin-Madison who also achieved a CR, the trial's overall response rate was 90% (nine out of 10). The combination of Pracinostat and azacitidine was well tolerated in the study; the most frequent side effects were nausea and fatigue.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEIP:US $6.90 USD 0.00

MEIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MEIP.
View Industry Companies

Industry Analysis


Industry Average

Valuation MEIP Industry Range
No financial data is available for MEIP.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEI PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at